According to New York Times, in a small clinical trial, 18 patients took a drug called Dostarlimab for around six months, and in the end, every one of them saw their tumours disappear.

The findings concerning dostarlimab, an antibody drug, in experimental treatment of rectal cancer patients is very encouraging but there is need for long-term studies to understand the real impact, an expert in cancer treatment has said. “This new trial at MSKCC in a small number of patients, with locally advanced rectal cancer patients who had MMR (MisMatch repair) deficiency, have shown total disappearance of tumor without any additional treatment in all 100 percent of them. This is very encouraging, but we must note that long term studies are required to understand the real impact,” Dr. (Col.) R. Ranga Rao, Chairman, Oncology, of Paras Hospitals in Gurugram said.

“The drug is still investigational, and the trial is limited to patients of a specific type , that constitute about 4 to 5 per cent of rectal cancers. While this is highly encouraging, we must not prematurely jump to conclusions that we have found a cure for all cancers, all stages, and no chemotherapy, surgery is ever required,” he added.

It is well recognized that Immunotherapy with PDL 1 blockers in MMRd patients is effective. “Already immunotherapy has made a big difference in the field of cancer of all types. Several earlier trials have shown encouraging responses,” Dr Rao said.

In what appears to be a miracle and ‘first time in history’, a small clinical trial has found that every single rectal cancer patient who received an experimental treatment found that their cancer had vanished.

Dr Luis A. Diaz J. of New York’s Memorial Sloan Kettering Cancer Center (MSKCC) said this was “the first time this has happened in the history of cancer”.

According to experts, Dostarlimab is a drug with laboratory-produced molecules, and it acts as substitute antibodies in the human body.

Overall, dostarlimab shows tremendous promise for the treatment of surgically resectable rectal cancer and may change the current treatment landscape drastically.

Reference:
https://www.firstpost.com/world/findings-about-dostarlimab-a-new-antibody-drug-very-encouraging-says-expert-in-cancer-treatment-10783881.html

More News
Maximising product potential with spray drying in CDMO
News · 02/03/2024

The pharmaceutical and biotechnology industries constantly seek innovative methods to enhance product stability, solubility, bioavailability and ease of use. Within this realm, CDMOs [Contract Development & Manufacturing Organizations] serve as invaluable partners in the development and production of high-quality drug products.

READ MORE
Chinese New Year | Red Sea crisis | Freight Rates
News · 05/02/2024

Chinese New Year 2024 is upon us, disrupting logistics from Asia starting Feb 10th. This event is expected to impact global shipping until Feb 21. Freight rates from Asia has skyrocketed with rates to the US surging by 3.5X and Europe by 6X.

READ MORE
Shipping Titans Battle Soaring Freight Expenses & Cargo Turbulence Amidst Red Sea Upheavel
News · 02/01/2024

Amid ongoing Red Sea diversions by shipping giants like Maersk, CMA, logistics managers are globally confronting a dual challenge of escalating ocean and air freight prices alongside cargo disruptions due to

READ MORE
Continuous manufacturing (CM): A game changer for pharma
News · 01/12/2023

Why will CM be the next generation on quality?

READ MORE
ICCM5 adopts new framework
News · 31/10/2023

The Fifth International Conference on Chemicals Management (ICCM5) concluded on 30 September in Bonn, Germany, by adopting “a comprehensive global framework that sets concrete targets and guidelines for key sectors across the entire lifecycle of chemicals”.

READ MORE
The Global Impact Of China’s Golden Week: Is Your Business Ready?
News · 29/09/2023

In October, the People’s Republic of China celebrates its annual national holiday, known as Golden Week. Similar to Chinese New Year, the entire country is on holiday, resulting in business closures and a potential 14-day halt in production and transportation of manufactured goods.

READ MORE
ECHA Adds Five Hazardous Chemicals To PIC
News · 08/09/2023

The European Chemicals Agency (ECHA) has amended the Prior Informed Consent (PIC) Regulation, EU 64/2012, to add 27 pesticides and eight industrial chemicals into Annex I, bringing the total to 295. As a result, EU exporters are now required to notify their intentions to export them from 1 November onwards.

READ MORE
Global Custom Synthesis & Manufacturing: Escalating Demand for Specialty Chemicals Drives Growth
News · 04/09/2023

The global custom synthesis and manufacturing market was valued at US$271.33 billion in 2022. The market value is expected to reach US$474.94 billion by 2028.

READ MORE
4 key Trends Reshaping Ocean freight Industry in 2023
News · 04/04/2023

The ocean freight industry is undergoing a massive transformation, as the technology and supply chain management tools are being improved by the day, impacting ocean freight rates.

READ MORE